MASH Therapies Show Fibrosis Signal in ALD, With Vijay Shah, MD
Audio narration · Coming soon
Phase 2 data indicate that therapies zalfermin, cagrilintide, and semaglutide improve fibrosis biomarkers in alcohol-related liver disease, as discussed by Dr. Vijay Shah.
Why this matters
PRISM scored this story 70/100 for interest.
Originally published by gnews